PDF(Pubmed)
Abstract：
(1) Background: Brown adipose tissue (BAT) is responsible for non-shivering thermogenesis, and its activation has become a new object as both a determinant of metabolic health and a target for therapy. This study aimed to identify the relationships between the presence of BAT, parameters that characterize metabolic health (glucose, lipids, blood pressure (BP)), and the dynamics of body mass index (BMI) during weight-reducing therapy. (2) Methods: The study included 72 patients with obesity. We investigated metabolic parameters, anthropometric parameters, and BP. Dual-energy X-ray absorptiometry (DXA) and positron emission tomography and computed tomography (PET/CT) imaging with 18F-fluorodeoxyglucose (18F-FDG) were performed. (3) Results: Before weight-reducing therapy, BAT was revealed only in 19% patients with obesity. The presence of BAT was associated with a lower risk of metabolic deviations that characterize metabolic syndrome: shorter waist circumference (WC) (p = 0.02) and lower levels of glucose (p = 0.03) and triglycerides (p = 0.03). Thereafter, patients were divided into four groups according to the type of therapy (only lifestyle modification or with Liraglutide or Reduxin or Reduxin Forte). We did not find a relationship between the presence of BAT and response to therapy: percent weight reduction was 10.4% in patients with BAT and 8.5% in patients without BAT (p = 0.78) during six months of therapy. But we noted a significant positive correlation between the volume of BAT and the effectiveness of weight loss at 3 months (r = 0.52, p = 0.016). The dynamic analysis of BAT after 6 months of therapy showed a significant increase in the volume of cold-induced metabolically active BAT, as determined by PET/CT with 18F-FDG in the Liraglutide group (p = 0.04) and an increase in the activity of BAT standardized uptake value (SUV mean and SUV max) in the Reduxin (p = 0.02; p = 0.01, respectively) and Liraglutide groups (p = 0.02 in both settings). (4) Conclusions: The presence of brown adipose tissue is associated with a lower risk of metabolic abnormalities. In general, our study demonstrated that well-established drugs in the treatment of obesity (Liraglutide and Reduxin) have one more mechanism for implementing their effects. These drugs have the ability to increase the activity of BAT. A significant positive relationship between the total volume of BAT and the percentage of weight loss may further determine the priority mechanism of the weight-reducing effect of these medicaments.
摘要：
（1）背景：棕色脂肪组织（BAT）负责非颤抖的产热，它的激活已成为代谢健康的决定因素和治疗目标的新目标。本研究旨在确定BAT的存在之间的关系，表征代谢健康的参数(葡萄糖，脂质，血压（BP），以及减重治疗期间体重指数（BMI）的动态。(2)方法:纳入72例肥胖患者。我们调查了代谢参数，人体测量参数,BP。使用18F-氟脱氧葡萄糖（18F-FDG）进行了双能X射线吸收法（DXA）和正电子发射断层扫描和计算机断层扫描（PET/CT）成像。（3）结果：减重治疗前，仅在19％的肥胖患者中发现了BAT。BAT的存在与代谢综合征特征的代谢偏差的风险较低相关：较短的腰围（WC）（p=0.02）和较低的葡萄糖水平（p=0.03）和甘油三酯（p=0.03）。此后,根据治疗类型(仅改变生活方式或使用利拉鲁肽或Reduxin或ReduxinForte)将患者分为4组.我们没有发现BAT的存在与治疗反应之间的关系：在六个月的治疗期间，BAT患者的体重减轻百分比为10.4％，而无BAT患者的体重减轻百分比为8.5％（p=0.78）。但是我们注意到BAT的体积与3个月时体重减轻的有效性之间存在显着正相关（r=0.52，p=0.016）。治疗6个月后BAT的动态分析显示，冷诱导的代谢活跃BAT的体积显着增加，通过PET/CT和18F-FDG在利拉鲁肽组(p=0.04)和Reduxin组(p=0.02;p=0.01)和利拉鲁肽组(在两种设置中p=0.02)的BAT标准化摄取值(SUV平均值和SUVmax)的活性增加。（4）结论：棕色脂肪组织的存在与代谢异常的风险较低有关。总的来说,我们的研究表明,公认的治疗肥胖的药物(利拉鲁肽和Reduxin)具有另一种发挥作用的机制.这些药物具有增加BAT活性的能力。BAT的总体积与体重减轻百分比之间的显著正相关可以进一步确定这些药物的减肥效果的优先机制。
